TerminatedPhase 2NCT00248534
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Lauren E. Abrey, MD, MDMemorial Sloan Kettering Cancer Center
- Intervention
- rituximab(biological)
- Enrollment
- 16 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2005 – 2012
Study locations (7)
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Duke Comprehensive Cancer Center, Durham, North Carolina, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
- M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00248534 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics